Drug Search Results
More Filters [+]

Tezosentan

Alternative Names: tezosentan, act-050089, act050089, act 050089
Latest Update: 2023-06-11
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ET Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tezosentan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Heart Failure, Acute|Heart Failure, Chronic|Pulmonary Heart Disease|Hypertension, Pulmonary|Heart Failure|Neuromyelitis Optica

Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2009-012450-20

P2

Completed

Hypertension, Pulmonary

2011-05-10

AC-051-207

P2

Terminated

Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary

2010-12-01

22%

AC-051-206

P2

Terminated

Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension

2010-11-01

2006-002907-15

P3

Completed

Neuromyelitis Optica|Heart Failure|Hypertension, Pulmonary|Pulmonary Heart Disease

2008-02-08

Recent News Events